Genomics of pulmonary arterial hypertension: impli... [Heart Fail Clin. 2010] - PubMed result

Heart Fail Clin. 2010 Jan;6(1):101-14.

Genomics of pulmonary arterial hypertension: implications for therapy.
Geraci MW, Bull TM, Tuder RM.

Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, AMC, MS C272, RC2, 12700 East 19th Avenue, Aurora, CO 80045, USA. mark.geraci@ucdenver.edu

Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.

PMID: 19945066 [PubMed - in process]

abrir aquí para acceder a éste y otros documentos NCBI NIH relacionados:
Genomics of pulmonary arterial hypertension: impli... [Heart Fail Clin. 2010] - PubMed result